288 related articles for article (PubMed ID: 34830871)
1. Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists.
Xing DT; Khor R; Gan H; Wada M; Ermongkonchai T; Ng SP
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830871
[TBL] [Abstract][Full Text] [Related]
2. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Taberna M; Oliva M; Mesía R
Front Oncol; 2019; 9():383. PubMed ID: 31165040
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
[TBL] [Abstract][Full Text] [Related]
7. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.
Plavc G; Strojan P
Radiol Oncol; 2020 Oct; 54(4):377-393. PubMed ID: 33064670
[TBL] [Abstract][Full Text] [Related]
8. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
10. Role of Immunotherapy in Head and Neck Cancer.
Ling DC; Bakkenist CJ; Ferris RL; Clump DA
Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
Brix N; Dunn L; Seiwert T; Belka C; Lauber K
Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
14. The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review.
Forner D; Horwich P; Trites JR; Hollenhorst H; Bullock M; Lamond NWD
Curr Oncol; 2020 Dec; 27(6):330-335. PubMed ID: 33380865
[TBL] [Abstract][Full Text] [Related]
15. Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer.
Tathineni P; Joshi N; Jelinek MJ
Curr Treat Options Oncol; 2023 Jun; 24(6):680-692. PubMed ID: 37067660
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of head and neck squamous cell carcinoma.
Pan Q; Gorin MA; Teknos TN
Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis.
Wang H; Zheng Z; Zhang Y; Bian C; Bao J; Xin Y; Jiang X
Front Pharmacol; 2023; 14():1269863. PubMed ID: 37795033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]